Tradestie Institutional Equity Comparison Engine

ZYME vs NUVB โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZYME Overall Edge

ZYME Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zymeworks Inc. (ZYME) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ZYME trades at 55.0x Forward P/E with 22.6% operating margin (+828.7% YoY revenue) versus NUVB at N/M Forward P/E and -61.2% operating margin (+242.6% YoY). In options structure, ZYME sits in CONSOLIDATION (45th %ile IV; Dealer Gamma Walls on Pro) against NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ZYME
ZYME 55.0x vs NUVB N/M Fwd P/E
Growth & Margin Winner ZYME
Op Margin 22.6% vs -61.2% ยท YoY +828.7% vs +242.6%
Momentum & Technical Winner ZYME
1Y +15.7% vs -46.9% ยท 52W Pos 44% vs 2%
Options & Structure Winner ZYME
CONSOLIDATION (45th %ile IV) vs BREAKDOWN (26th %ile IV)
ZYME NASDAQ
Zymeworks Inc.
Pharmaceutical Preparations
$26.14
-2.68% 1D
Market Cap $1.9B
1M Return -8.09%
1Y Return +15.66%
Forward P/E 55.0x
Unified AI Score
59.5 / 100 HOLD
Tech 60.0 Fund 59.0 Flow 67.0 Mom 50.0
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZYME +15.66% NUVB -46.85% Spread: +62.51 pp (ZYME Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ZYME Revenue NUVB Revenue ZYME Op. Margin NUVB Op. Margin Margin Edge
FY2020 $40M N/A -481.3% N/A ZYME
FY2021 $30M N/A -808.2% N/A ZYME
FY2022 $410M N/A 31.6% N/A ZYME
FY2023 $80M N/A -181.6% N/A ZYME
FY2024 $80M $10M -179.7% -7527.3% ZYME
FY2025 $110M $60M -87.3% -338.7% ZYME

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZYME (8) vs NUVB (2)
Institutional Metric ZYME NUVB Criterion Row Winner
Market Capitalization Scale $1.9B $1.3B Larger Scale ZYME
Trailing P/E Ratio Valuation 50.7x N/M Lower Multiple ZYME
Forward P/E Ratio Valuation 55.0x N/M Lower Multiple ZYME
Revenue Growth (YoY) Growth +828.7% +242.6% Higher Growth ZYME
Operating Margin (TTM) Profitability 22.6% -61.2% Higher Margin ZYME
Net Profit Margin Profitability 16.3% -67.4% Higher Margin ZYME
Return on Equity (ROE) Capital Efficiency 15.0% -49.1% Higher ROE ZYME
52-Week Range Position Momentum 44% ($22โ€“$32) 2% ($4โ€“$10) Stronger Trend ZYME
Beta / 30D Volatility Risk Regime 0.87ฮฒ ยท 56% Vol 1.52ฮฒ ยท 55% Vol Lower Realized Risk NUVB
Unified Institutional Score Composite Signal 59.5 / 100 (HOLD) 61.0 / 100 (BUY) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZYME vs NUVB Buy Guide
ZYME CONSOLIDATION
56d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 45th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ZYME Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZYME nor NUVB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.